Abeona Therapeutics (ABEO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ABEO Stock Forecast


Abeona Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a -0.66% downside from ABEO’s last price of $6.04) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ABEO Price Target


The average price target for Abeona Therapeutics (ABEO) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential -0.66% downside from ABEO's last price of $6.04.

ABEO Analyst Ratings


Buy

According to 3 Wall Street analysts, Abeona Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ABEO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Abeona Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 14, 2022-Leerink Partners$6.00$4.1544.58%-0.66%
Row per page
Go to

The latest Abeona Therapeutics stock forecast, released on Nov 14, 2022 by Leerink Partners company, set a price target of $6.00, which represents a 44.58% increase from the stock price at the time of the forecast ($4.15), and a -0.66% decrease from ABEO last price ($6.04).

Abeona Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.04$6.04$6.04
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Abeona Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Abeona Therapeutics's last price of $6.04. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 03, 2024H.C. Wainwright-BuyInitialise
May 16, 2024Cantor FitzgeraldOverweightOverweightHold
Nov 14, 2022SVB LeerinkMarket PerformMarket PerformHold
Row per page
Go to

Abeona Therapeutics's last stock rating was published by H.C. Wainwright on Jul 03, 2024. The company Initialise its ABEO rating from "null" to "Buy".

Abeona Therapeutics Financial Forecast


Abeona Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 22Mar 22Dec 20Sep 20Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Jun 15Mar 12Mar 11Jun 10Sep 09Jun 08Jun 02
Revenue--------$68.00K$346.00K$3.00M$7.00M---$2.60M$186.00K$235.00K$282.00K$1.85M$150.00K$105.00K$144.00K--
Avg Forecast$9.15M$3.50M$125.00K$125.00K$100.00K$100.00K$100.00K$166.67K$1.00M$253.73K$5.37M$1.40M$120.00K$300.00K$778.50K$559.44K$219.23K$183.53K$232.65K$2.58M$160.71K$172.86K$87.03K$118.53K$216.67K
High Forecast$9.15M$3.50M$125.00K$125.00K$100.00K$100.00K$100.00K$166.83K$1.00M$304.48K$5.37M$1.40M$120.00K$300.00K$778.50K$671.33K$263.07K$220.23K$279.18K$3.09M$192.86K$207.43K$104.43K$142.24K$260.00K
Low Forecast$9.15M$3.50M$125.00K$125.00K$100.00K$100.00K$100.00K$166.50K$1.00M$202.99K$5.37M$1.40M$120.00K$300.00K$778.50K$447.55K$175.38K$146.82K$186.12K$2.06M$128.57K$138.28K$69.62K$94.82K$173.33K
# Analysts333345443171016810161820191014101510118
Surprise %--------0.07%1.36%0.56%5.00%---4.64%0.85%1.28%1.21%0.72%0.93%0.61%1.65%--

Abeona Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $166.67K, with a low forecast of $166.50K, and a high forecast of $166.83K. ABEO's average Quarter revenue forecast represents a 145.10% increase compared to the company's last Quarter revenue of $68.00K (Dec 22).

Abeona Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 22Mar 22Dec 20Sep 20Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Jun 15Mar 12Mar 11Jun 10Sep 09Jun 08Jun 02
# Analysts333345443171016810161820191014101510118
EBITDA--------$-10.37M$-13.31M$-13.34M$-4.81M$-15.34M$-21.87M$-16.90M$-8.29M$-5.00M$-5.37M$-3.98M$-4.67M$-1.67M$1.99M$-3.87M--
Avg Forecast$-5.49M$-2.10M$-75.00K$-75.00K$-60.00K$-60.00K$-60.00K$-100.00K$-600.00K$-9.52M$-3.22M$-840.00K$-72.00K$-180.00K$-13.20M$-8.72M$-5.66M$-3.72M$-3.13M$-11.41M$-1.78M$-103.71K$-1.67M$-1.83M$-1.46M
High Forecast$-5.49M$-2.10M$-75.00K$-75.00K$-60.00K$-60.00K$-60.00K$-99.90K$-600.00K$-7.62M$-3.22M$-840.00K$-72.00K$-180.00K$-10.56M$-6.98M$-4.53M$-2.97M$-2.51M$-9.12M$-1.43M$-82.97K$-1.33M$-1.46M$-1.17M
Low Forecast$-5.49M$-2.10M$-75.00K$-75.00K$-60.00K$-60.00K$-60.00K$-100.10K$-600.00K$-11.43M$-3.22M$-840.00K$-72.00K$-180.00K$-15.84M$-10.47M$-6.79M$-4.46M$-3.76M$-13.69M$-2.14M$-124.46K$-2.00M$-2.19M$-1.75M
Surprise %--------17.29%1.40%4.14%5.72%213.06%121.48%1.28%0.95%0.88%1.44%1.27%0.41%0.94%-19.21%2.32%--

10 analysts predict ABEO's average Quarter EBITDA for Mar 11 to be $-1.78M, with a high of $-1.43M and a low of $-2.14M. This is -189.48% lower than Abeona Therapeutics's previous annual EBITDA (Jun 10) of $1.99M.

Abeona Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 22Mar 22Dec 20Sep 20Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Jun 15Mar 12Mar 11Jun 10Sep 09Jun 08Jun 02
# Analysts333345443171016810161820191014101510118
Net Income--------$6.42M$-20.99M$-15.83M$-7.24M$-17.37M$-23.92M$-18.55M$-8.46M$-5.25M$-5.54M$-4.11M$-4.89M$-1.90M$1.79M$-4.07M--
Avg Forecast$-8.20M$-18.19M$-21.77M$-21.26M$-20.11M$-20.11M$-17.52M$-26.30M$-38.42M$-10.16M$-128.07M$-183.56M$-558.01M$-467.53M$-14.50M$-8.91M$-5.95M$-3.84M$-3.24M$-11.95M$-2.03M$2.44M$-1.75M$-1.99M$-1.85M
High Forecast$-8.20M$-18.19M$-21.77M$-21.26M$-20.11M$-19.05M$-17.52M$-26.30M$-38.42M$-8.13M$-128.07M$-183.56M$-558.01M$-467.53M$-11.60M$-7.13M$-4.76M$-3.07M$-2.59M$-9.56M$-1.62M$2.93M$-1.40M$-1.59M$-1.48M
Low Forecast$-8.20M$-18.19M$-21.77M$-21.26M$-20.11M$-21.16M$-17.52M$-26.30M$-38.42M$-12.20M$-128.07M$-183.56M$-558.01M$-467.53M$-17.40M$-10.69M$-7.14M$-4.61M$-3.89M$-14.34M$-2.43M$1.95M$-2.10M$-2.39M$-2.22M
Surprise %---------0.17%2.07%0.12%0.04%0.03%0.05%1.28%0.95%0.88%1.44%1.27%0.41%0.94%0.73%2.32%--

Abeona Therapeutics's average Quarter net income forecast for Mar 24 is $-26.30M, with a range of $-26.30M to $-26.30M. ABEO's average Quarter net income forecast represents a -509.92% decrease compared to the company's last Quarter net income of $6.42M (Dec 22).

Abeona Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 22Mar 22Dec 20Sep 20Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Jun 15Mar 12Mar 11Jun 10Sep 09Jun 08Jun 02
# Analysts333345443171016810161820191014101510118
SG&A--------$5.68M$4.22M$7.40M$4.43M$4.70M$5.61M$5.66M$2.88M$3.02M$4.37M$3.67M$979.00K$1.03M$1.25M$3.46M--
Avg Forecast$51.52M$19.71M$703.86K$703.86K$563.09K$563.09K$563.09K$938.48K$5.63M$1.43M$30.22M$7.88M$675.71K$1.69M$4.38M$3.15M$1.23M$1.03M$1.31M$2.39M$904.96K$973.34K$490.04K$667.43K$1.22M
High Forecast$51.52M$19.71M$703.86K$703.86K$563.09K$563.09K$563.09K$939.42K$5.63M$1.71M$30.22M$7.88M$675.71K$1.69M$4.38M$3.78M$1.48M$1.24M$1.57M$2.87M$1.09M$1.17M$588.04K$800.91K$1.46M
Low Forecast$51.52M$19.71M$703.86K$703.86K$563.09K$563.09K$563.09K$937.54K$5.63M$1.14M$30.22M$7.88M$675.71K$1.69M$4.38M$2.52M$987.56K$826.74K$1.05M$1.91M$723.96K$778.66K$392.02K$533.94K$976.01K
Surprise %--------1.01%2.96%0.24%0.56%6.96%3.32%1.29%0.91%2.45%4.22%2.80%0.41%1.13%1.29%7.06%--

Abeona Therapeutics's average Quarter SG&A projection for Mar 24 is $938.48K, based on 4 Wall Street analysts, with a range of $937.54K to $939.42K. The forecast indicates a -83.48% fall compared to ABEO last annual SG&A of $5.68M (Dec 22).

Abeona Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 22Mar 22Dec 20Sep 20Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Jun 15Mar 12Mar 11Jun 10Sep 09Jun 08Jun 02
# Analysts333345443171016810161820191014101510118
EPS--------$0.82$-3.62$-4.26$-1.93$-8.73$-12.22$-9.67$-4.50$-3.26$-4.23$-4.00$-253.26$-123.37$80.09$-416.95--
Avg Forecast$-0.16$-0.35$-0.42$-0.41$-0.39$-0.39$-0.34$-0.51$-0.75$-2.38$-2.50$-3.58$-10.89$-9.13$-7.95$-5.00$-4.25$-2.25$-1.77$213.75$-200.00$-187.50$-123.75$-487.50$-750.00
High Forecast$-0.16$-0.35$-0.42$-0.41$-0.39$-0.37$-0.34$-0.51$-0.75$-2.38$-2.50$-3.58$-10.89$-9.13$-7.95$-4.00$-3.40$-1.80$-1.42$256.50$-160.00$-150.00$-99.00$-390.00$-600.00
Low Forecast$-0.16$-0.35$-0.42$-0.41$-0.39$-0.41$-0.34$-0.51$-0.75$-2.38$-2.50$-3.58$-10.89$-9.13$-7.95$-6.00$-5.10$-2.70$-2.13$171.00$-240.00$-225.00$-148.50$-585.00$-900.00
Surprise %---------1.09%1.52%1.70%0.54%0.80%1.34%1.22%0.90%0.77%1.88%2.26%-1.18%0.62%-0.43%3.37%--

According to 4 Wall Street analysts, Abeona Therapeutics's projected average Quarter EPS for Mar 24 is $-0.51, with a low estimate of $-0.51 and a high estimate of $-0.51. This represents a -162.60% decrease compared to ABEO previous annual EPS of $0.82 (Dec 22).

Abeona Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CALACalithera Biosciences$0.01$2.0019900.00%Hold
ATHAAthira Pharma$0.64$18.002712.50%Buy
IVVDInvivyd$0.90$9.50955.56%Buy
RVPHReviva Pharmaceuticals$1.00$10.00900.00%Buy
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
CKPTCheckpoint Therapeutics$3.49$20.00473.07%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
CABACabaletta Bio$4.00$16.33308.25%Buy
RGNXREGENXBIO$8.76$34.00288.13%Buy
ADAPAdaptimmune Therapeutics$0.83$2.83240.96%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
PDSBPDS Bio$3.23$9.00178.64%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
AFMDAffimed$3.27$7.50129.36%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
ACADACADIA Pharmaceuticals$14.62$26.5781.74%Buy
MREOMereo BioPharma Group$4.01$6.7568.33%Buy
LPTXLeap Therapeutics$3.67$5.5049.86%Buy
ABEOAbeona Therapeutics$6.04$6.00-0.66%Buy

ABEO Forecast FAQ


Yes, according to 3 Wall Street analysts, Abeona Therapeutics (ABEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ABEO's total ratings.

Abeona Therapeutics (ABEO) average price target is $6 with a range of $6 to $6, implying a -0.66% from its last price of $6.04. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ABEO stock, the company can go down by -0.66% (from the last price of $6.04 to the average price target of $6), down by -0.66% based on the highest stock price target, and down by -0.66% based on the lowest stock price target.

ABEO's average twelve months analyst stock price target of $6 does not support the claim that Abeona Therapeutics can reach $9 in the near future.

Abeona Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $466.67K (high $466.83K, low $466.5K), average EBITDA is $-280K (high $-280K, low $-280K), average net income is $-84.029M (high $-82.97M, low $-85.087M), average SG&A $2.63M (high $2.63M, low $2.63M), and average EPS is $-1.64 (high $-1.62, low $-1.661). ABEO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $12.9M (high $12.9M, low $12.9M), average EBITDA is $-7.74M (high $-7.74M, low $-7.74M), average net income is $-69.412M (high $-69.412M, low $-69.412M), average SG&A $72.64M (high $72.64M, low $72.64M), and average EPS is $-1.355 (high $-1.355, low $-1.355).

Based on Abeona Therapeutics's last annual report (Dec 2022), the company's revenue was $1.41M, beating the average analysts forecast of $1.25M by 12.78%. Apple's EBITDA was $-44.685M, beating the average prediction of $-10.122M by 341.46%. The company's net income was $-31.809M, missing the average estimation of $-48.585M by -34.53%. Apple's SG&A was $17.26M, beating the average forecast of $7.06M by 144.43%. Lastly, the company's EPS was $-4.05, beating the average prediction of $-3.125 by 29.60%. In terms of the last quarterly report (Dec 2022), Abeona Therapeutics's revenue was $68K, missing the average analysts' forecast of $1M by -93.20%. The company's EBITDA was $-10.372M, beating the average prediction of $-600K by 1628.67%. Abeona Therapeutics's net income was $6.42M, missing the average estimation of $-38.42M by -116.70%. The company's SG&A was $5.68M, beating the average forecast of $5.63M by 0.91%. Lastly, the company's EPS was $0.82, missing the average prediction of $-0.75 by -209.33%